A 2025 PMC review highlights a critical challenge in pharmaceutical development: drug candidates face a 96% attrition rate, with costs reaching $2.6 billion per approved compound. This staggering inefficiency stems from fundamental structural mismatches in how human drug response is predicted. Traditional preclinical tools—animal models and static lab tests—capture only isolated biological moments and cannot represent the genetic and physiological diversity of real patient populations. A mouse liver differs fundamentally from a human liver, and single cell lines fail to account for variable drug metabolism, receptor differences, and immune responses that only emerge during human trials, by which point development resources are exhausted. Digital twin technology addresses these limitations by enabling continuous data exchange between virtual and physical systems, creating dynamic models that integrate molecular interactions with full-body drug behavior and patient-specific variations. Unlike static simulations, true digital twins update constantly with new research and trial findings, providing comprehensive biological representation across multiple scales. This distinction between one-time models and trusted regulatory-grade digital twins represents the frontier in transforming preclinical drug efficacy modeling and reducing the staggering failure rates plaguing the industry.

Immune checkpoint blockade has improved outcomes in triple-negative breast cancer, yet treatment failures often involve heterogeneous biological mechanisms requiring tailored therapeutic approaches. This narrative review evaluates how biomarkers can guide patient selection for established immunotherapy regimens versus investigational strategies targeting immune exclusion and resistance. PD-L1 testing remains clinically relevant for first-line pembrolizumab combinations in advanced TNBC, though it is not required for the KEYNOTE-522 early-stage perioperative regimen. Sacituzumab govitecan combined with pembrolizumab is an approved first-line option for PD-L1-positive advanced disease, though its benefits reflect regimen-level efficacy rather than validated immunological synergy. Alternative biomarkers including stromal lymphocytes, spatial immune organization, and circulating tumor DNA provide complementary prognostic information but lack evidence as PD-L1 replacements. Emerging strategies involving epigenetic modulation, adenosine blockade, DNA-damage signaling, and local immune priming show variable evidence, with some demonstrating negative randomized findings. The review emphasizes that robust biomarker frameworks must specify disease context, assay methodology, proposed clinical action, and evidence that treatment changes improve patient outcomes. Prospective validation of these biomarker-treatment links is essential before implementing resistance-directed combinations clinically.

A recent workshop at Health Canada, organized by BioCanRx, addressed how to enable Canadian patients to receive cell therapies manufactured locally rather than waiting weeks for imported treatments. The discussion centered on closed system automation as a key enabler for decentralized cell therapy manufacturing. Integrated manufacturing platforms like the Octane Cocoon can simplify production processes, reduce cleanroom space requirements, and enable faster patient access by shortening vein-to-vein time. Workshop participants reached consensus on four critical priorities: implementing end-to-end automated platforms to bring manufacturing closer to patients, establishing clear regulatory guidance and simplified commercialization pathways with Health Canada, adopting closed automation early in development to avoid costly comparability studies during scale-up, and fostering collaboration among Canadian organizations to build next-generation healthcare infrastructure. The discussion highlighted that decentralized manufacturing models are already proven globally and remain underutilized in Canada. Early engagement with regulators and automation adoption from the start are essential for reducing investment risk and accelerating market entry for cell therapies in Canada.

Cell and gene therapies are expanding rapidly beyond oncology and rare diseases, with 4,487 therapies in development globally and 54 already FDA-approved. At the Academy of Managed Care Pharmacy's Nexus 2026 meeting in San Diego, experts proposed establishing a national, all-payer risk pool to address financing challenges threatening health plan viability. The presentation revealed that gene therapy programs in development grew across clinical phases, with 438 in the U.S. pipeline as of January. However, oncologists report treating twice as many patients on these therapies compared to 2024, while 34% of patient dropoffs stem from insurance approval barriers. With list prices ranging from two to four million dollars per single claim, 76% of payers anticipate affordability becoming a moderate to major challenge within two to three years. The proposed solution involves all-payer participation, per-member monthly fees paired with manufacturer outcomes-based contracts, federal administration, and eligibility restricted to rarest or highest-cost therapies. This mechanism would enable patient tracking across plan changes, providing a sustainable reimbursement pathway essential as gene therapy applications expand into immunology, neurology, and cardiovascular indications.

# Summary Researchers have published a comprehensive review examining the therapeutic applications and obstacles associated with mRNA-lipid nanoparticle (mRNA-LNP) technology in hematology and oncology. This open-access article, appearing in the Journal of Hematology & Oncology in October 2026, synthesizes current knowledge about how mRNA-LNP platforms deliver genetic instructions to treat blood disorders and cancer. The review explores significant advances in formulation strategies and delivery mechanisms that have improved therapeutic efficacy, while simultaneously addressing substantial challenges including immunogenicity concerns, biodistribution optimization, and manufacturing scalability. The analysis highlights the potential of mRNA-LNP approaches for personalized medicine in oncology and innovative treatments for hematologic malignancies. This work matters because mRNA-LNP technology represents a paradigm shift in therapeutic development, offering rapid customization for individual patient needs and disease variants. Understanding both achievements and remaining hurdles is critical for researchers and industry stakeholders advancing next-generation cancer and blood disorder treatments. The review provides essential guidance for further clinical translation and regulatory pathways.

CAR-T cell therapy represents a transformative treatment for relapsed or refractory leukemia and lymphoma, yet patient access remains severely limited by high costs—ranging from $462,000 to $594,000 in 2025—and centralized manufacturing. Only 5.4% of eligible U.S. patients with diffuse large B-cell lymphoma receive CAR-T therapy, with similarly low adoption rates in Europe. Point-of-care manufacturing, where CAR-T cells are produced within or adjacent to treating hospitals under licensed quality systems, offers a compelling solution to expand access. Prospective clinical studies demonstrate that hospital-manufactured CAR-T products achieve efficacy and safety comparable to commercial alternatives, with response rates and toxicity profiles aligning with registration trial data. The CLIC-01 trial exemplified manufacturing reliability, achieving 100% success rates across 29 manufacturing runs with all participants receiving target doses. This decentralized approach removes critical barriers preventing eligible patients from receiving treatment, positioning hospital-based manufacturing as a practical pathway to democratize access to this revolutionary cellular gene therapy platform.

Sickle cell gene therapy offers promising treatment options but presents significant financial and logistical challenges for patients. Two therapies have received U.S. approval: exagamglogene autotemcel (Casgevy), developed by Vertex Pharmaceuticals for patients ages 2 and older, and lovotibeglogene autotemcel (Lyfgenia), made by Genetix Biotherapeutics for patients ages 12 and older. List prices reach $2.2 million and $3.1 million respectively, though actual out-of-pocket costs vary based on insurance coverage and individual circumstances. Beyond therapy expenses, patients face additional costs including conditioning chemotherapy, hospital stays, and travel to treatment centers. Insurance coverage differs across Medicaid, private plans, and Medicare, with state Medicaid programs bearing particular financial pressure. The voluntary Cell and Gene Therapy Access Model helps participating states manage costs through outcome-based agreements with manufacturers. Understanding available coverage options, insurance requirements, and support resources remains essential for patients navigating this complex treatment landscape.

Gene Therapy journal is advancing research transparency and standardization within the field while actively soliciting negative results from cystic fibrosis gene therapy studies. The publication is participating in NISO/STM's Working Group on Peer Review Terminology to establish consistent definitions and terminology standards for peer review practices across the scientific community. Additionally, the journal has launched a special initiative featuring editorial team members, beginning with Editor-in-Chief Janine Scholefield, to enhance engagement with authors and readers. Recognizing that gene therapy shows considerable promise for treating cystic fibrosis but faces significant safety challenges, the journal is encouraging researchers to submit brief reports detailing negative or unsuccessful findings from early-stage through clinical CF gene therapy trials. This initiative acknowledges that unpublished negative results are essential for comprehensive risk evaluation and preventing wasteful, redundant research that could potentially harm patients. The submission deadline for this Special Issue is May 31, 2025, representing a meaningful effort to foster greater transparency and scientific rigor in an evolving therapeutic field.

Merck has discontinued Recarbrio, an intravenous antibiotic combination approved in 2019 for multidrug-resistant gram-negative infections. The drug combines imipenem, cilastatin, and relebactam to counter resistance mechanisms like KPC enzymes found in carbapenem-resistant Enterobacterales. Originally indicated for complicated urinary tract infections, intra-abdominal infections, and hospital-acquired pneumonia, Recarbrio's label expanded to children in 2025. Merck cited an ongoing portfolio review unrelated to safety or quality concerns. Infectious disease specialists acknowledge an immediate though narrow clinical gap, particularly for patients with difficult-to-treat Pseudomonas aeruginosa infections. The discontinuation highlights vulnerabilities in the antibiotic market's payment model for reserved drugs. Experts point to the PASTEUR Act's subscription-style purchasing proposal as a potential solution to sustain antibiotic development and availability, emphasizing that unsustainable economics—rather than clinical inadequacy—drove the withdrawal.

The Centers for Medicare and Medicaid Services announced that all state Medicaid programs, plus the District of Columbia and Puerto Rico, have applied to participate in GENEROUS, a five-year voluntary model launched in January 2026. The initiative aims to control escalating Medicaid drug costs through CMS-facilitated negotiations between manufacturers and state agencies, with manufacturers providing supplemental rebates to align Medicaid prices with international benchmarks. With Medicaid net drug spending reaching $60 billion in 2024—a $10 billion increase from 2022—the model addresses unsustainable cost growth while building on existing programs like the Medicaid Drug Rebate Program and the Cell and Gene Therapy Access Model. Under GENEROUS, participating manufacturers offer lower drug prices based on international reference pricing in exchange for standardized coverage criteria across all participating states. The model is voluntary for both manufacturers and states, with applications finalized by September 30, 2026. By leveraging international pricing data, GENEROUS enables state Medicaid programs to negotiate lower drug costs while ensuring broader patient access to life-saving medications and providing manufacturers with expanded market opportunities through streamlined coverage requirements.

Researchers at University College London and the University of Cambridge have developed personalized computational models of triple-negative breast cancer (TNBC) using patient genomic data to create tumor "digital twins" that predict treatment responses and identify targeted therapies to overcome drug resistance. Published in Cell Reports Medicine, the study employed symbolic artificial intelligence—an approach based on logical rules and biological interactions rather than statistical pattern recognition—to generate interpretable predictions. Using genomic data from 31 patients in the PARTNER clinical trial, which evaluated combination chemotherapy with or without the PARP inhibitor olaparib, the models correctly predicted treatment responses in 74% of cases. For 10 of 13 patients with incomplete treatment responses, the models predicted that adding targeted therapy could achieve pathological complete response. ATM inhibition emerged as the most promising strategy, particularly for tumors with genetic alterations associated with increased DNA replication stress. Since TNBC accounts for approximately 15% of breast cancers and lacks receptors targeted by conventional drugs, this personalized modeling approach offers significant potential to optimize treatment selection and improve outcomes in this difficult-to-treat cancer subtype.

This research evaluates the cost-effectiveness of combining ribociclib, a cyclin-dependent kinase 4/6 inhibitor, with aromatase inhibitors compared to aromatase inhibitor monotherapy for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer in pre- and postmenopausal women with stage II and III disease. Conducted from a Canadian payer perspective, the analysis assesses the economic implications of adding ribociclib to standard endocrine therapy in this patient population. The study addresses a critical healthcare decision point regarding whether the clinical benefits of combination therapy justify additional treatment costs within Canada's healthcare system. By examining incremental cost-effectiveness ratios and quality-adjusted life years, this research provides evidence to guide resource allocation and formulary decisions for early breast cancer management, informing both clinicians and policymakers about the value proposition of CDK4/6 inhibitor-based adjuvant strategies in Canada's healthcare context.

Researchers at Stanford University and collaborating institutions have developed a comprehensive framework for digital biomarkers to advance the diagnosis and monitoring of neurodegenerative diseases. Published in Nature Reviews Bioengineering, this work addresses the critical need for objective, non-invasive measurement tools that can detect disease progression earlier than traditional clinical assessments. The framework integrates multiple technological approaches including wearable sensors, smartphone-based applications, and artificial intelligence algorithms to capture behavioral, motor, and cognitive changes characteristic of conditions like Alzheimer's disease, Parkinson's disease, and ALS. These digital biomarkers leverage machine learning to identify subtle patterns in gait, voice, tremor, and cognitive performance that correlate with neurodegeneration. The significance of this work lies in its potential to enable earlier diagnosis, facilitate more precise patient stratification for clinical trials, and support real-world monitoring of therapeutic interventions. By combining rigorous validation methodologies with practical implementation strategies, the framework establishes a blueprint for translating digital health technologies into clinically actionable tools that could substantially improve outcomes in neurodegenerative disease management.

Nepal's sixth national prevalence drug-resistant tuberculosis survey, published in October 2024 in Infectious Diseases of Poverty, provides critical epidemiological data on the burden of drug-resistant TB in the country. This open-access research represents the latest comprehensive assessment of drug-resistant tuberculosis prevalence across Nepal's population, building on previous national surveys to track trends over time. The study examines the extent of resistance to first-line and second-line anti-tuberculosis medications, offering essential information for understanding disease patterns and treatment challenges. By documenting current prevalence figures, the survey identifies the scale of drug-resistant TB as a public health concern in Nepal and informs strategic responses to combat the disease. The findings are significant for policymakers and healthcare professionals, as drug-resistant tuberculosis poses substantial challenges to TB control programs, requiring more complex and costly treatment regimens. This prevalence data enables Nepal's health authorities to allocate resources effectively, strengthen surveillance systems, and implement targeted interventions to address drug-resistant TB and improve patient outcomes.

Advances in CRISPR gene editing and stem cell-derived embryo models offer significant biomedical promise, but approved therapies command extraordinary costs, ranging from $2.2 million for Casgevy to $4.25 million for Lenmeldy, raising critical questions about equitable access. This article addresses how affordability, accessibility, ethical compliance, and distributive inequality can be measured through a single coherent index to inform policy decisions. The authors audited an existing Genomic Equity Accessibility Framework (GEAF) and identified fundamental mathematical flaws, including dimensional incompatibility and unbounded outputs. They reconstructed GEAF' as a normalized, bounded (0–100) weighted composite incorporating six dimensionless components—accessibility, ethical compliance, affordability, equity, policy strength, and research efficiency—using multi-attribute utility theory. Testing across seven scenarios anchored to actual list-price data revealed GEAF' ranging from 27.9 to 86.5, with cost and inequality factors identified as primary drivers. Monte Carlo sensitivity analysis demonstrated no overlap between baseline and equity-intervention scenarios, establishing GEAF' as a mathematically rigorous tool for evaluating genomic therapy distribution policies and supporting evidence-based decision-making.

The CGTS 2026 conference, co-chaired by Burt Zweigenhaft, PhD, DLitt, of AVBCC, opens registration with a comprehensive agenda addressing critical challenges in cell and gene therapy. The event begins with McKesson and InspiroGene's 2026 State of the Industry Report, presented by Joe DePinto, Head of Cell and Gene Advanced Therapies, offering insights into industry opportunities and obstacles. A fireside chat featuring industry leaders including Nicole Verdun from Verdun Advisors and Madan Jagasia, MD, CEO of Obsidian Therapeutics, moderated by Marc Samuels of ADVI Health, examines pressing issues such as supply chain dynamics, manufacturing challenges, and expanding care into community settings. A pivotal panel discussion, moderated by Scott Wallace, MD, JD, explores the fundamental economic tension when transformative therapies arrive before robust business models exist. Panelists including Lesli Marasco and Will Shrank, former CMO of Humana and CEO of Aradigm, address how payers, employers, and providers can recognize long-term value while managing near-term budgetary pressures. Additional sessions tackle translating scientific promise into real-world product effectiveness, underscoring the industry's evolution beyond laboratory success toward practical clinical and commercial viability.

Blood tests are revolutionizing Alzheimer's disease diagnosis, transforming a historically complex, time-consuming process into a simple, accessible screening tool. Traditionally, diagnosis required cognitive examinations combined with invasive and expensive procedures such as cerebrospinal fluid analysis via lumbar puncture or PET brain imaging to detect tau tangles and amyloid plaques. These barriers contributed to approximately 75% of dementia cases remaining undiagnosed globally. Advanced blood testing technologies now detect the same biomarkers—tau and amyloid proteins—that clinicians previously sought through invasive procedures, eliminating months of waiting and uncertainty. This shift enables faster diagnosis without unnecessary lumbar punctures or PET scans in many cases, allowing patients and families to transition from limbo to actionable planning regarding treatment options, care arrangements, and future preparations. For clinicians, the increased accessibility of blood-based biomarkers promises earlier intervention opportunities and better resource allocation in primary care settings, fundamentally improving diagnostic equity and patient outcomes across diverse populations.

Two groundbreaking gene therapies, Casgevy and Lyfgenia, are transforming treatment options for sickle cell disease by potentially eliminating severe pain crises in eligible patients. However, significant barriers threaten widespread adoption. High treatment costs, complex procedural requirements, and a shortage of sickle cell specialists have limited patient access to these therapies. Beyond individual treatment availability, experts identify critical gaps in the broader sickle cell care infrastructure, revealing that current healthcare systems are inadequately equipped to support comprehensive patient management. These challenges have prompted coordinated efforts to establish more robust treatment networks across the nation, ensuring patients can access both the innovative gene therapies and the specialized medical support necessary for optimal outcomes. Addressing these systemic issues is essential to translating scientific breakthroughs into tangible health improvements for sickle cell disease patients.

Antisense oligonucleotides, or ASOs, are synthetic DNA-like strands designed to bind specific RNA molecules and suppress disease-causing protein production. A new open-access review in Molecular Biology Reports by Abhigna Nagaraj and colleagues at JSS Academy of Higher Education and Research examines the computational toolkit revolutionizing ASO engineering, from sequence selection through three-dimensional structural prediction, molecular docking, and molecular dynamics simulation. ASOs offer distinct advantages over conventional small-molecule drugs and monoclonal antibodies due to their programmability—researchers can design molecules targeting virtually any RNA sequence with high specificity and reproducible manufacturing. Unlike small molecules requiring protein surface pockets, ASOs target RNA directly, enabling treatment of previously undruggable diseases. The field has evolved through multiple generations of chemical modifications to enhance stability and cellular uptake. First-generation phosphorothioate backbones replaced non-bridging oxygen with sulfur for nuclease resistance; second-generation chemistry added 2'-O-methyl or 2'-O-methoxyethyl modifications and chimeric gapmer designs; third-generation chemistries include locked nucleic acids. With multiple approved drugs and dozens in clinical trials, ASOs represent a leading precision medicine platform for personalized therapies, particularly benefiting rare genetic disorders lacking alternative treatments.

Neoantigen cancer vaccines represent a transformative personalized medicine approach, with artificial intelligence playing a crucial role in identifying which tumor mutations to target. In August 2026, Merck and Moderna announced that their personalized mRNA neoantigen vaccine successfully met both primary endpoints in a phase 3 melanoma trial involving over one thousand patients, marking the first neoantigen vaccine to clear phase 3 testing. The treatment workflow involves sequencing individual tumors, using AI models to rank thousands of candidate mutations, and manufacturing patient-specific vaccines. However, despite high benchmark performance scores, prediction models demonstrate significant limitations in clinical practice. While leading classifiers like NetMHCpan-4.0-L and MHCflurry-L report area-under-curve scores exceeding 0.97, published experimental data reveals that only 53 of 1,948 predicted peptide-MHC combinations successfully triggered measurable T-cell responses. This discrepancy between laboratory predictions and clinical outcomes highlights both the promise and remaining challenges in neoantigen vaccine development, establishing a new paradigm for precision oncology while revealing where predictive algorithms still require refinement.